Unlikely as due diligence process is currently being advised by...

Unlikely as due diligence process is currently being advised by the team at Macquarie bank, with an accelerated timeline (more a confirmation of existing knowledge/work) to achieve a binding offer by end of this month first week of February.

They are confident of funding through new equity and debt issuance, with potential third party involvement.

The focus here is to seal the deal with speed, as the share price has been trading at historically low weighted average prices  - the speed removes uncertainty for all including Jangho shareholders, their focus is on dialogue with HLS board to achieve exclusive endorsement/acceptance for the scheme of arrangement. Timing of offer was to maximize chance of rapidly moving to a binding  exclusive - minimizing chances of a competitive bid, as most firms are still coming out from the Christmas / New Year season.

This is the logical next step, having achieved success in bringing the VEI model to China. They are positioning HLS as a good buy to their shareholders given HLS being number 1 or 2 in Australia for the following services, and how they can replicate this for China:

1) GP network

2) Medical imaging hospital

3) Pathology 

source: Their announcement to Shanghai Stock Exchange:

http://static.sse.com.cn/disclosure/listedinfo/announcement/c/2019-01-03/601886_20190103_3.pdf